 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded on September 5, 2007 and is headquartered in San Diego, CA.

Current Price	$1.30
Prev Close	$1.33
Open	$1.34
Dividend Yield	0.00%
50-Day Moving Average	$1.24
Beta	0.83
Avg. Volume	43,388.95
PE Ratio	-0.71

52-Week High	$3.00
52-Week Low	$0.76
Market Capitalization	$25.32M
EPS	-$1.83
Price to Book	0.82
Revenue Per Employee	N/A
Enterprise Value/EBITDA	0.35

RGLS Regulus Therapeutics Inc

About

Feed

Fundamentals

News